Lenalidomide Adherence in Older Adults

The Washington University

Status: Terminated

Conditions: Multiple Myeloma

Treatments: Other: Medication Event Monitoring System

Study type: Observational

Funder types: Other

Identifiers

NCT03779555

201812141

Details and patient eligibility

About

To describe patterns of adherence and pilot baseline measures to investigate factors associated with lower adherence to lenalidomide in older adults with myeloma.

Enrollment: 17 patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥65
• Receiving lenalidomide for treatment of multiple myeloma.
• Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
• Able to read and understand English.
• Able to understand and willing to sign an IRB-approved written informed consent document.

Exclusion criteria

• Estimated life expectancy <6 months.
• Anticipated duration of lenalidomide therapy <3 months.
• Residing in a nursing facility where their medications are administered to them OR patient reports they do not self-administer their own medications.

Trial design

17 participants in 1 patient group

Patients taking lenalidomide for multiple myeloma

Description:

-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)

Treatment:

Other: Medication Event Monitoring System